nasdaq:admp
|
3713669
|
Feb 2nd, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Feb 1st, 2024 10:55PM
|
Feb 2nd, 2024 01:49PM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Feb 1st, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 31st, 2024 09:33PM
|
Feb 1st, 2024 10:46AM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 31st, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 30th, 2024 09:38PM
|
Jan 31st, 2024 11:53AM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 30th, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 29th, 2024 09:33PM
|
Jan 30th, 2024 05:46PM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 29th, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 28th, 2024 09:44PM
|
Jan 29th, 2024 11:27AM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 28th, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 27th, 2024 09:42PM
|
Jan 27th, 2024 09:42PM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 27th, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 26th, 2024 09:37PM
|
Jan 27th, 2024 04:39PM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 26th, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 25th, 2024 09:36PM
|
Jan 26th, 2024 04:29PM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 25th, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 24th, 2024 08:04PM
|
Jan 24th, 2024 09:56PM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:admp
|
3713669
|
Jan 24th, 2024 12:00AM
|
DMK Pharmaceuticals Corporation
|
2.3K
|
16.00
|
Open
|
|
Jan 24th, 2024 05:46AM
|
Jan 24th, 2024 05:46AM
|
DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
|
Open
|
|
Open
|
11682 El Camino Real, Suite 300
|
San Diego
|
CA
|
US
|
92130
|
|
Adamis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|